Upstream Bio, Inc.
UPB$1.67B
Small CapNASDAQBiotechnology🇺🇸North America52 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 1, 2026
35wMarket Overview
Stock performance and key metrics
UPB News
Catalyst Timeline
1 upcoming, 1 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Verekitug (UPB-101) | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps | - | - |
Verekitug | Phase 2 | Severe Asthma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply